- Went public, Nov 2019
- Acquired Zorronet, Apr 2026
- Acquired Dr. Frucht Systems , Apr 2026
About
BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria in the treatment of chronic diseases, such as cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis, and colorectal cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.
The company's platforms use computational and synthetic biology and research from Doctors Rotem Sorek, Eran Elinav, and Eran Segal of the Weizmann Institute of Science and Doctor Timothy K. Lu of the Massachusetts Institute of Technology.
With the establishment of X Security & Defense, BiomX intends to expand its presence in security and defense markets by identifying and commercializing technologies that address evolving operational needs across national security, emergency response, and critical infrastructure protection.
Funding history · 10 rounds · $146.5M total
Q&A
- What was BiomX's most recent funding round?
- In December 2025, BiomX completed a funding round, raising $3 million.
- Which company did BiomX acquire in April 2026?
- In April 2026, BiomX acquired Zorronet, an autonomous AI command-and-control platform for real-time defense and security applications.
- What was the outcome of BiomX's Phase 1b/2a trial for BX004 in cystic fibrosis patients?
- In November 2023, BiomX announced positive topline results from Part 2 of the Phase 1b/2a trial evaluating BX004 for the treatment of chronic pulmonary infections in patients with Cystic Fibrosis.
- What was a significant development for BiomX in the security and defense sector in March 2026?
- In March 2026, BiomX launched a security subsidiary in Israel and announced an initial investment of over $3 million in its operations.
- What was the purpose of the collaboration between BiomX and Boehringer Ingelheim in June 2022?
- In June 2022, BiomX collaborated with Boehringer Ingelheim to discover inflammatory bowel disease microbiome biomarkers.
- What was the outcome of the FDA feedback for BiomX's next-generation phage cocktail program in November 2025?
- In November 2025, BiomX announced positive FDA feedback supporting its next-generation phage cocktail program for diabetic foot infections.
- What was the status of BiomX's BX004 program in Cystic Fibrosis in July 2025?
- In July 2025, BiomX announced the successful initiation of a Phase 2b trial with the first patient dosed in the BX004 program for patients with Cystic Fibrosis.
- What was a key leadership change at BiomX in March 2026?
- In March 2026, BiomX named Michael Oster as Chief Executive Officer and David Rokach as Chief Financial Officer to support its next phase of growth.
Team · 3
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | biomx.com |
|---|---|
| linkedin.com/company/18049975 | |
| facebook.com/Biomx-2286421221606645 |
Identifiers & details
| Former names | MBcure |
|---|---|
| Founded | 2015-5 |
| Employees (exact) | 62 |
| Market cap | $2.9M |
| Status reason | Public on NYSE on Nov 2019; |
Acquisitions & public offerings
| Acquired | Date | Amount |
|---|---|---|
| Zorronet | 2026-04 | |
| Dr. Frucht Systems | 2026-04 | |
| Adaptive Phage Therapeutics | 2024-03 | |
| RondinX | 2017-12 | — |
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| 2021-07 | $15.0M | |||
| 2019-11 |